Publications

September 2023 (Revised April 2024)
Case

Atomwise: Strategic Opportunities in AI for Pharma

By: Satish Tadikonda

Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details

Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Biotechnology Industry; Biotechnology Industry

January 2014
Supplement

Amgen Inc.: Pursuing Innovation and Imitation? (B)

By: Ian Mackenzie

The (B) case reveals that Sharer decided that Amgen should enter the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The... View Details

Keywords: Corporate Strategy; Biotechnology Industry; Biotechnology Industry; United States

June 2012
Case

GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships

By: Arthur A. Daemmrich and Ian McKown Cornell

Three years into a major public-private partnership between GlaxoSmithKline and Fiocuz, Brazil's principal health institute, the company assesses technology transfer and joint research under the agreement. GSK was selling its Synflorix vaccine (against pediatric... View Details

Keywords: Public-Private Partnerships; Business and Government Relations; Foreign Direct Investment; Health Care and Treatment; Globalized Firms and Management; Biotechnology Industry; Biotechnology Industry; Brazil

April 2011
Supplement

Roche's Acquisition of Genentech (CW)

By: Bo Becker

Spreadsheet for case 210040. View Details

Keywords: Biotechnology Industry; Biotechnology Industry

March 2011 (Revised June 2012)
Case

Office of Technology Transfer - Shanghai Institutes for Biological Sciences

By: Willy Shih, Sen Chai, Kamen Bliznashki and Courtney Hyland

Gordon Zong is trying to teach Chinese universities and research institutes how to do effective technology transfer and IP licensing, but he is trying to do it in an environment with weak property rights and an underdeveloped support infrastructure. As the managing... View Details

Keywords: Multinational Firms and Management; Patents; Knowledge Management; Law Enforcement; Business and Government Relations; Research and Development; Biotechnology Industry; Biotechnology Industry; China

24 Jun 2008
Conference Presentation

The effect of heterogeneous institutional actors on entrepreneurial activity and resource attainment in the U.S. biodiesel industry

By: Shon R. Hiatt

Keywords: Entrepreneurship; Biotechnology Industry; Biotechnology Industry; United States

2010
Working Paper

Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe

By: Christopher C. Liu and Toby E. Stuart

In innovative industries, private-sector companies increasingly are participants in open communities of science and technology. To participate in the system of exchange in such communities, firms often publicly disclose what would otherwise remain private discoveries.... View Details

Keywords: For-Profit Firms; Higher Education; Information Publishing; Innovation and Invention; Science-Based Business; Social and Collaborative Networks; Boundaries; Biotechnology Industry; Biotechnology Industry

Read Now

November 2007
Class Lecture

The Baby Business (FSS)

By: Debora L. Spar

In vitro fertilization and genetic screening are possible with the advent of biotechnology. International adoptions, surrogacy, and other approaches to family planning are on the rise. But few rules govern these measures, medical costs can be prohibitive, and... View Details

Keywords: Governing Rules, Regulations, and Reforms; Policy; Demand and Consumers; Business and Government Relations; Business and Stakeholder Relations; Genetics; Societal Protocols; Commercialization; Biotechnology Industry; Biotechnology Industry

Find at Harvard

November 2007
Case

Antegren: A Beacon of Hope

By: Joshua D. Margolis, Thomas J. DeLong and Terence Heymann

The CEO of Biogen Idec faces a set of difficult decisions regarding a promising drug for Multiple Sclerosis that is headed for early approval by the FDA. The first in a series focuses on operational decisions triggered by the drive for early approval. Sparks discussion... View Details

Keywords: Demand and Consumers; Leadership; Ethics; Corporate Social Responsibility and Impact; Decision Choices and Conditions; Crisis Management; Health Testing and Trials; Biotechnology Industry; Biotechnology Industry

June 2004 (Revised May 2005)
Case

Judah Folkman and the War on Cancer

Judah Folkman, professor in the Division of Vascular Biology at Children's Hospital in Boston, is considering how best to advance the research in his lab in an era where biomedical research has gotten more interdisciplinary and collaborative. Specifically, Folkman has... View Details

Keywords: Conflict of Interests; Leadership; Research; Personal Development and Career; Health Care and Treatment; Collaborative Innovation and Invention; Biotechnology Industry; Biotechnology Industry; Boston

Find at Harvard

September 1995
Case

Ares-Serono

By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop

Ares Serono, a medium-size Swiss pharmaceutical company, is the global leader in the field of fertility drugs. The company has successfully transformed into one of the very few biotech firms in Europe. The case treats a set of major strategic and organizational... View Details

Keywords: Geographic Location; Globalized Firms and Management; Asset Management; Balance and Stability; Expansion; Digital Platforms; Leadership Development; Health Care and Treatment; Transformation; Family Business; Problems and Challenges; Biotechnology Industry; Biotechnology Industry; Switzerland; Europe

Find at Harvard

02 Aug 2004
Research & Ideas

Health Care Research and Prospects

is a lot other work at the school going on around these issues by many other faculty. For instance, Dave Scharfstein is doing great work on how capital market forces influence the development strategies of biotechnology companies. David... View Details

Keywords: by Wendy Guild Swearingen; Health

August 2013
Course Overview Note

Building Life Science Businesses Fall 2013: Course Outline and Syllabus

By: Richard G. Hamermesh

This Course Outline and Syllabus gives an overview of the Fall 2013 class Building Life Science Businesses. View Details

Keywords: Healthcare Ventures; Entrepreneurial Management; Entrepreneurship; Entrepreneurs; Health Care and Treatment; Health Testing and Trials; Medical Specialties; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Asia; North America; Europe